Ind-Swift Labs.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE915B01019
  • NSEID: INDSWFTLAB
  • BSEID: 532305
INR
316.95
-13.25 (-4.01%)
BSENSE

Nov 20

BSE+NSE Vol: 5.4 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Fredun Pharma
Shukra Pharma.
Sakar Healthcare
Unichem Labs.
Solara Active
RPG LifeScience.
Ind-Swift Labs.
Hikal
Indoco Remedies
Advanced Enzyme
Sai Parenteral's
Why is Ind-Swift Laboratories Ltd ?
1
Weak Long Term Fundamental Strength with a -10.13% CAGR growth in Operating Profits over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.59 times
  • The company has been able to generate a Return on Equity (avg) of 6.94% signifying low profitability per unit of shareholders funds
2
With a growth in Net Profit of 324.75%, the company declared Outstanding results in Sep 26
  • The company has declared positive results for the last 5 consecutive quarters
  • PAT(Q) Highest at Rs 34.68 cr.
  • NET SALES(Q) Highest at Rs 240.46 cr
  • PBDIT(Q) Highest at Rs 45.46 cr.
3
Stock is technically in a Mildly Bullish range
  • Multiple factors for the stock are Bullish like MACD, KST and OBV
4
With ROE of 6.3, it has a Very Expensive valuation with a 1.9 Price to Book Value
  • The stock is trading at a fair value compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 232.23%, its profits have risen by 255.9% ; the PEG ratio of the company is 0.2
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Ind-Swift Labs. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ind-Swift Labs. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Ind-Swift Labs.
232.23%
3.63
63.98%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-4.32%
EBIT Growth (5y)
-10.13%
EBIT to Interest (avg)
16.03
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.64
Tax Ratio
20.08%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.98%
ROCE (avg)
8.43%
ROE (avg)
6.94%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
30
Industry P/E
40
Price to Book Value
1.87
EV to EBIT
33.52
EV to EBITDA
23.07
EV to Capital Employed
2.16
EV to Sales
3.18
PEG Ratio
0.15
Dividend Yield
NA
ROCE (Latest)
6.43%
ROE (Latest)
6.29%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

31What is working for the Company
PAT(Q)

Highest at Rs 34.68 cr.

NET SALES(Q)

Highest at Rs 240.46 cr

PBDIT(Q)

Highest at Rs 45.46 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 18.91%

PBT LESS OI(Q)

Highest at Rs 36.36 cr.

EPS(Q)

Highest at Rs 3.94

-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 340.35 cr

Loading Valuation Snapshot...
Here's what is working for Ind-Swift Labs.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 36.36 cr has Grown at 2492.11%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 34.68 cr has Grown at 334.0%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
At Rs 240.46 cr has Grown at 51.58%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 34.68 cr. and Grown
each quarter in the last five quarters
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 240.46 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 45.46 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 18.91%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 36.36 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 3.94
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Ind-Swift Labs.
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 340.35 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents